Lytix Biopharma will present two posters at SITC in Washington
Lytix Biopharma is present at the Society for Immunotherapy of Cancer's (SITC) 32nd Annual Meeting, November 8-12 in Washington with two posters. One poster describes LTX-315`s ability to reshape the tumor microenvironment and thereby making the tumors more sensitive to immune checkpoint inhibitors and chemotherapy. The second poster presents the effect of LTX-315 in cancer patients, including LTX-315`s ability to turn cold tumors hot.
Friday, November 10 Poster Number: P493 Title: LTX-315: A first-in-class oncolytic peptide that reshapes the tumor microenvironment
Saturday, November 11 Poster Number: P250 Title: LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the patients with advanced metastatic tumors: Results from an ongoing study.
CEO Edwin Klumper comments:
‘’It is exciting to see that the patient data confirm the translation of the preclinical capacity of LTX-315 to prime tumors for systemic response.’’
SITC is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.